M

Moderna

Develops mRNA-based medicines for health

Director, Analytical Development

Full-TimeUpdated on 10/23/2026
$167k - $300.7k+ Annual discretionary bonus + Other incentive compensation + Equity award
Expert
Bachelor's, Master's, PhD
Norwood, MA, USA
In Person100% onsite in Norwood, Massachusetts.
Biology & BiotechBioprocess & Biomanufacturing
No H1B Sponsorship

About the job

Requirements
  • A Ph.D. in Analytical Chemistry, Biochemistry, Pharmaceutical Sciences, Chemical Engineering, Bioengineering, or a related scientific field with 12 or more years of relevant industry experience, or an M.S. or B.S. with 18 or more years of relevant experience in analytical development, analytical technology, pharmaceutical sciences, or related areas for biologics, vaccines, or advanced therapeutic modalities.
  • Demonstrated ability to define and execute an analytical innovation or technology strategy and translate emerging science into methods and capabilities adopted in development or GMP Quality Control environments.
  • Deep scientific expertise in analytical method development, broad understanding across multiple analytical domains, and ability to assess strengths, limitations, and intended-use suitability of emerging technologies.
  • Strong understanding of analytical procedure lifecycle principles, including analytical target profiles, robustness and risk assessment, qualification or validation, method transfer, continued performance monitoring, and lifecycle change management; practical knowledge of ICH Q14 and Q2(R2) is strongly preferred.
  • Proven experience moving new analytical technologies from concept or proof of concept through implementation, including cross-functional alignment, technology transfer, validation strategy, change control, and adoption within clinical or commercial testing networks.
  • Strong knowledge of GMP, data integrity, global regulatory expectations, and inspection readiness, with scientific judgment to balance innovation, phase-appropriate development, compliance, and operational scalability.
  • Experience leading complex, matrixed initiatives across Analytical Development, QC, AST/MS&T, Process Development, Manufacturing, Quality, Regulatory, Digital, and external partners, and ability to influence senior stakeholders without relying solely on direct authority.
  • Strong external orientation and ability to build productive collaborations with technology vendors, academic groups, consortia, CROs/CDMOs, and peer organizations to identify, evaluate, and accelerate high-value analytical innovation.
  • Demonstrated success developing high-performing scientific talent and creating an environment where rigorous experimentation, learning, prioritization, and execution translate into scalable organizational capabilities.
  • Excellent scientific communication, executive presence, stakeholder management, and organizational leadership skills.
Responsibilities
  • Lead the Innovative Technology and Methodology capability within Analytical Development, establishing the vision, scientific strategy, portfolio, and roadmap for next-generation analytical methods and technologies across clinical and commercial products.
  • Build and govern an end-to-end analytical innovation pipeline that identifies unmet analytical needs, evaluates emerging technologies, prioritizes opportunities, develops proof-of-concept solutions, and advances successful technologies through development, qualification or validation strategy, transfer, and implementation.
  • Partner with Analytical Sciences, APLs, AST, and QC to translate product knowledge, control-strategy needs, method performance trends, investigations, and network pain points into prioritized innovation programs with clear analytical target profiles and intended-use requirements.
  • Drive development and modernization of analytical methodologies across separation sciences, molecular and sequencing technologies, biophysical and spectroscopic methods, bioassays, microbiology, advanced characterization, and other emerging analytical platforms appropriate to mRNA and advanced therapeutic modalities.
  • Lead method transformation across the QC network by enabling replacement, simplification, consolidation, and harmonization of legacy methods with more robust, higher-throughput, automation-ready, and scalable platform approaches where scientifically and regulatorily justified.
  • Partner with AST, QC, ATO, Quality, Regulatory, Digital, and Automation teams to establish implementation pathways for innovative methods, including bridging, transfer, validation, change management, digital integration, training, and sustained method performance across internal and external testing sites.
  • Embed science- and risk-based analytical development principles consistent with evolving global expectations, including ICH Q14 and Q2(R2), ensuring new methodologies are fit for intended purpose, appropriately robust, lifecycle-ready, and supported by a defensible regulatory strategy.
  • Establish an external innovation network across instrument and technology vendors, biotechnology companies, academic collaborators, consortia, and other external partners; scout emerging capabilities and determine where external innovation can accelerate Moderna analytical strategy.
  • Advance automation-, digital-, and data-enabled analytical methodologies in partnership with relevant functions, designing methods and workflows that reduce manual variability, improve data integrity and review efficiency, and enable scalable deployment across the analytical network.
  • Define success measures and business cases for the innovation portfolio, including improvements in method robustness, invalid/OOS/OOT rates, turnaround time, throughput, labor intensity, cost, method harmonization, and successful network adoption; use measures to prioritize investment and stop or redirect low-value efforts early.
  • Develop, coach, and inspire scientific talent while creating a culture that combines curiosity and experimentation with disciplined execution, technical rigor, cross-functional accountability, and focus on translating innovation into sustained organizational impact.
  • Work 100% onsite to support work, collaborate closely with colleagues, and contribute to site-based operations.
Desired Qualifications
  • Experience with analytical automation, high-throughput workflows, digital integration, advanced data analysis, AI/ML-enabled analytical applications, or other laboratory-of-the-future capabilities.
  • Experience with mRNA, nucleic acids, lipid nanoparticles, vaccines, biologics, or other advanced modalities, and understanding of how analytical technologies support product characterization, control strategy, comparability, stability, and manufacturing.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 23rd, 2026
Moderna sees $114.9M in net ETF buying as CGGO adds $121.1M stake

ETFs bought $114.9 million of Moderna stock on Wednesday, October 21, ending a one-day net selling streak. Twenty ETFs were buyers and 10 were sellers. CGGO led with 492,604 shares worth $121.1 million, a 1.06% portfolio weight. IBB added $2.0 million and QQQM $1.0 million. The flows followed a $7.5 million net outflow on October 20 and a $26.1 million net inflow on October 19. Over the last five reported days, ETFs were net buyers on three and net sellers on two. Moderna has a market cap of $80.9 billion. Its trailing 12-month revenue was $2.23 billion, down 27.3% over one year, and the shares have returned 587.11% so far this year.

Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.